|
GSK PLC on Friday reported positive preliminary results from a phase 3 trial regarding its 5-in-1 meningococcal ABCWY vaccine candidate. Subjects in the trial were healthy individuals aged between 10 and 25 and received two doses of the vaccine candidate given six months apart. The Brentford, England-based pharmaceutical company said the study showed no inferiority of the vaccine candidate in the primary endpoints for the five Neisseria meningitidis serogroups A,B,C,W and Y in the individuals when compared to two doses of meningococcal group B vaccine Bexsero plus one dose of the meningococcal group A, C, W-135, and Y conjugate vaccine Menveo. Neisseria meningitidis bacteria can cause diseases such as meningitis, an infection of the protective membranes around the brain and spinal cord, and life-threatening sepsis, under which a body’s immune system overreacts to an infection and damages the body’s own tissues and organs. Chief Scientific Officer Tony Wood said: ‘It’s particularly encouraging to see the breadth of coverage against the broadest panel of circulating MenB strains to date, as we know MenB is the most common cause of meningococcal disease in the US with the lowest immunisation rate.’ GSK shares were 1.9% higher at 1,472.20 pence each in London on Friday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
